ReviewDrug design, development and therapy2025
Advanced Natural Therapeutics and Delivery Strategies for Diabetic Foot Ulcers: A Mini Review.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ginsenosides in Modern Pharmaceutics: Mechanisms, Applications, Challenges, and Perspectives.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot ulcers (DFUs) are a severe complication of diabetes mellitus with complex pathophysiology. Conventional therapies often lead to poor healing and high recurrence. This mini-review highlights the promise of advanced natural therapeutics and delivery strategies for DFU management. We focus on bioactive natural compounds, such as ginsenosides, astragalus polysaccharides, and resveratrol, that target critical processes like hyperglycemia, vascular impairment, and oxidative stress by modulating key signaling pathways. To improve bioavailability, innovative delivery systems including nanotechnology and nitric oxide-releasing platforms have been developed, enabling sustained release and enhanced healing. Clinical evidence shows promising results, such as shortened healing time and improved ulcer closure rates, supports the translational potential of standardized natural formulations. Moving forward, priorities should focus on standardizing natural formulations, optimizing delivery, and conducting rigorous clinical trials. With continued innovation, natural therapeutics hold significant potential to improve wound healing, reduce amputations, and enhance the quality of life for DFU patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.